New Delhi: Daiichi Sankyo, which has a
majority stake in Ranbaxy Laboratories, today said it is going
to launch some of Ranbaxy's generic medicine in the Japanese
market soon.
"There is a debate going on in Japan on how to reduce
healthcare cost by increasing the generic share to 30 per
cent. Soon we will be launching Ranbaxy's generic drugs in the
Japanese market," Daiichi Sankyo Senior Executive Officer,
Global Corporate Strategy and Member of Board, Tsutomu Une,
told reporters on the sidelines of the India Economic Summit.
Asked about the time frame, he said, "It is only a matter
of time."
The company is working on a synergy plan with Ranbaxy
under which Daiichi Sankyo's product will be introduced in
emerging markets through Ranbaxy, he said, declining to give
further details.
Asked about Ranbaxy's USFDA issue, he said Daiichi is
working to resolve the matter, adding that Ranbaxy has no
issue with the Japanese drug regulator.
Last year, the USFDA had banned 30 generic drugs produced
at Ranbaxy's plants at Poanta Sahib (in Himachal Pradesh) and
Dewas (in Madhya Pradesh) citing violation of good
manufacturing practice.
Subsequently, the Application Integrity Policy (AIP) was
imposed on Poanta Sahib facility, which meant the company's
drug applications were not reviewed.
Bureau Report
First Published: Monday, November 09, 2009, 15:46